News

If you’re hunting for asymmetric upside heading into 2025, Ruvi AI (RUVI) is building the kind of momentum that turns ...
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...